Phase II trial of prednimustine in glioblastoma multiforme.
Twenty-one consecutive patients with histologically confirmed glioblastoma multiforme were treated with prednimustine (130 mg/m2 for 5 days every 3 weeks) adjuvant to surgery and radiation therapy. A median survival of 8.7 months was obtained, and prednimustine seems to be of limited effectiveness. Toxicity was acceptable and primarily hematologic.